With the recent developments in the atopic dermatitis (AD) market, the field is becoming more competitive as novel therapies are soon anticipated to enter the market. This evolution may benefit AD ...

The facility is set to produce DS for biopharmaceuticals, leveraging the company's protein engineering and antibody ...

As work progresses on an up-and-coming biologics plant in North Carolina, specialty pharma company Kyowa Kirin has completed ...

Amgen today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the month's most ...

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and onl ...

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Approximately 60% to 85% of patients who develop ...